Guggenheim Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $46

Futu NewsJan 23 22:31 · Ratings

Express News | Immunovant Inc : Guggenheim Raises Target Price to $46 From $44

BreakingsJan 23 19:30

Argenx Cut to Sell at Deutsche Bank on Valuation

Seeking AlphaJan 18 03:54

Immunovant, Inc. (IMVT): The Biotech Stock With Biggest Upside Potential

Yahoo FinanceJan 18 00:10

Insider Trading: Immunovant's (IMVT) Major Investor Boosts Stake by $337M

TipRanksJan 16 19:20

Roivant Sciences Increases Stake in Immunovant With $336.9 Million Purchase

InvestingJan 16 05:40